

Preferred term recorded for ILD type event

- Pneumonitis x 11
- Lung infiltration x 2
- ILD x 2
- Radiation pneumonitis x 1
- Radiation fibrosis x 1

Clinical experience data in Oriental and Asian patients

	RR	DCR	MST	References
Korea EAP, n=111	26%	40%	8.8M	Clinical Cancer Research 2004;10(13):4383-8
Taiwan EAP, n=109	23.9%	62.4%	12.8M	Internal on file
China registration trial, n=159	27%	54.1%	NA	Internal on file
China EAP, n=31	35.5%	58%	11.5M	BMC Cancer 2004, 4 17-24
Singapore, n=33	39%	50%	NA	American Society of Clinical Oncology 2003;22:694, Abs 2790
Thailand EAP, n=27	36%	72%	NA	1 st Asia Pacific lung cancer society meeting

Clinical trial data/experiences in Japanese patients

	ORR	Disease control rate	Median survival (months)	1 year survival	References
IDEAL1 Japanese patients n=102	27%	66%	11.8	50%	JCO 2003; 21:2237-2246
Takano et al, n=98	33%	62%	10.7M	45%	Lung Cancer 2004; 45: 93-104
Kaneda et all, n=101	20%	72%	NA	NA	Lung Cancer 2004; 46:247-254
Hotta et al, n=57	27%	73%	~11.8M	NA	Lung Cancer 2004; 46: 255-261
Katakami et al, n=51	37%	57%	~10M	NA	ASCO 2004, Abs. 2679
Goto et al, n=222	27%	65%	NA	NA	ASCO 2004, Abs. 7059


Definition of pack years exposure

- On the CRF, the following data are collected in patients who smoke:
 - Number of cigarettes smoked in a week
 - Date patient started and stopped smoking


Pack years = number packs per day × number years smoked

Survival by reason for stopping prior chemotherapy

— IRESSA - - - - - Placebo



MONTHS :	0	2	4	6	8	10	12
AT RISK :	1529	1213	776	416	221	93	28



MONTHS :	0	2	4	6	8	10	12
AT RISK :	163	136	100	68	31	10	3